AXSM Stock Analysis: Buy, Sell, or Hold?
AXSM - Axsome Therapeutics, Inc
$184.25
-1.01 (-0.55%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 17, 2026
16d
Get Alerted When AXSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AXSM shows positive signals but monitor for confirmation. Market pricing in 4.4% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: AXSM shows positive signals but monitor for confirmation. Market pricing in 4.4% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.27
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$8.24
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AXSM is currently trading at $184.25, which is considered slightly high relative to its 30-day fair value range of $160.74 to $186.00. From a valuation perspective, the stock is trading at a premium (Forward PE: 488.9) compared to its historical average (429.6). At these levels, the market is pricing in 4.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AXSM is in a strong uptrend. Immediate support is located at $172.05, while resistance sits at $191.50.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $212.94 (+14.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AXSM is in a strong uptrend. Immediate support is located at $172.05, while resistance sits at $191.50.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $212.94 (+14.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$160.74 -
$186.00
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($212.94)
- NEUTRAL: Market pricing in 4.4% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$160.74 -
$186.00
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$9.12
(4.9%)
Support & Resistance Levels
Support Level
$172.05
Resistance Level
$191.50
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
488.95
Wall Street Target
$212.94
(+14.9%)
Revenue Growth (YoY)
63.2%
Profit Margin
-40.9%
Valuation Premium vs History
+4.4% premium
PE vs Historical
489.0 vs 429.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.4%
(market-implied from PE analysis)
1-Year Target
$193.42
(+4%)
2-Year Target
$201.93
(+9%)
3-Year Target
$210.81
(+14%)
3-Yr Target (if PE normalizes)
(PE: 489→430)
PE COMPRESSION
$185.22
(0%)
Earnings growth offset by PE compression
Last updated: January 30, 2026 7:47 PM ET
Data refreshes hourly during market hours. Next update: 8:47 PM
Data refreshes hourly during market hours. Next update: 8:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AXSM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Herriot Tabuteau
SELL
12774 shares
2025-10-08
Herriot Tabuteau
SELL
13390 shares
2025-10-07
Herriot Tabuteau
SELL
19220 shares
2025-10-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced AXSM Option Strategies
Professional options setups generated by AI based on today's AXSM price and gamma walls.
